IHAM
VKTX icon

Integral Health Asset Management’s Viking Therapeutics VKTX Stock Holding History

Integral Health Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300,000
Closed -$24.6M – 101
2024
Q1 		$24.6M Buy
+300,000
New +$13.3M 2.28% 10

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Integral Health Asset Management's VKTX Position: Q1 2026 in Review

Integral Health Asset Management increased its Viking Therapeutics (VKTX) stake by 150% in Q1 2026, buying an estimated $4.82M and bringing the position to 250,000 shares worth $8.13M. The position accounts for 0.39% of the portfolio, ranked #68.

Integral Health Asset Management first reported a position in VKTX in Q4 2022 and has held it in 10 quarters since. The position peaked at $36.9M in Q1 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Integral Health Asset Management held 250,000 shares of Viking Therapeutics worth $8.13M as of Q1 2026.
  • Integral Health Asset Management bought 150,000 Viking Therapeutics shares in Q1 2026, an estimated $4.82M.
  • Viking Therapeutics made up 0.39% of Integral Health Asset Management's portfolio in Q1 2026, its #68 holding.
  • Integral Health Asset Management first reported a position in Viking Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Integral Health Asset Management's Viking Therapeutics position peaked at $36.9M in Q1 2024.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.